个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Shi, Yuankai[1] * ; Fang, Jian[2] ; Xing, Ligang[3] ; Yao, Yu[4] ; Zhang, Jian[5] ; Liu, Lian[6] ; Wang, Yongsheng[7] ; Hu, Changlu[8] ; Xiong, Jianping[9] ; Liu, Zhihua[10] ; Yang, Runxiang[11] ; Wang, Zhen[12] ; Zhao, Enfeng[13] ; Wang, Mengzhao[14] ; Zhao, Yanqiu[15] ; Tang, Kejing[16] ; Li, Zhihua[17] ; Song, Zhengbo[18] ; Li, Yongsheng[19] ; Zhuang, Wu[20] ; Jin, Bo[21] ; Cheng, Ying[22] ; Hu, Yanping[23] ; Gu, Yanhong[24] ; Wu, Lin[25] ; Ma, Rui[26] ; Yu, Qitao[27] ; Yu, Yan[28] ; Zhao, Jun[2] ; Zhao, Hui[29] ; Lv, Dongqing[30] ; Shang, Yanhong[31] ; Xing, Puyuan[1] ; Zhou, Jin[32] ; Li, Xingya[33] ; Liu, Zhe[34] ; Dai, Zhaoxia[35] ; Xia, Guohao[36] ; Chen, Xueqin[37] ; Ba, Yi[38] ; Bai, Chunmei[14] ; Li, Qingshan[39] ; An, Guangyu[40] ; Hu, Weiguo[41] ; Wang, Yinxiang[42] ; Wang-Gillam, Andrea[43] ; Ding, Yuli[42] ; Li, Qiao[42] ; Rao, Zhiyue[42] ;
机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted D, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp,Dept Med Oncol, Beijing, Peoples R China [2]Beijing Canc Hosp, Beijing, Peoples R China [3]Shandong Canc Hosp, Jinan, Peoples R China [4]Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China [5]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [6]Shandong Univ, Dept Orthoped, Jinan, Peoples R China [7]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [8]Anhui Prov Canc Hosp, Hefei, Peoples R China [9]Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China [10]Jiangxi Canc Hosp, Nanchang, Peoples R China [11]Yunnan Canc Hosp, Kunming, Peoples R China [12]Linyi Canc Hosp, Linyi, Peoples R China [13]Hebei Prov Cangzhou Hosp Integrated Tradit Chinese, Cangzhou, Peoples R China [14]Peking Union Med Coll Hosp, Beijing, Peoples R China [15]Henan Canc Hosp, Zhengzhou, Peoples R China [16]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Peoples R China [17]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China [18]Zhejiang Canc Hosp, Hangzhou, Peoples R China [19]Chongqing Canc Hosp, Chongqing, Peoples R China [20]Fujian Canc Hosp, Fuzhou, Peoples R China [21]China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China [22]Jilin Canc Hosp, Changchun, Peoples R China [23]Hubei Canc Hosp, Wuhan, Peoples R China [24]Jiangsu Prov Hosp, Nanjing, Peoples R China [25]Hunan Canc Hosp, Changsha, Peoples R China [26]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China [27]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China [28]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [29]Anhui Med Univ, Hosp 2, Hefei, Peoples R China [30]Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China [31]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China [32]Sichuan Canc Hosp, Chengdu, Peoples R China [33]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [34]Capital Med Univ, Affiliated Beijing Chest Hosp, Beijing, Peoples R China [35]Dalian Med Univ, Hosp 2, Dalian, Peoples R China [36]Jiangsu Canc Hosp, Nanjing, Peoples R China [37]Hangzhou Canc Hosp, Hangzhou, Peoples R China [38]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [39]Chengde Med Univ, Dept Pathol, Chengde, Peoples R China [40]Capital Med Univ, Affiliated Beijing Chaoyang Hosp, Beijing, Peoples R China [41]Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China [42]Jacobio Pharmaceut Co Ltd, Beijing, Peoples R China [43]Jacobio US Pharmaceut Inc, Burlington, MA USA
出处：
DOI： 10.1038/s41591-024-03401-z
ISSN：

摘要：
Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRASG12C-mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC). Between 15 September 2022 and 28 September 2023, 119 patients with a median age of 62 years were enrolled. As of the data cut-off date on 28 March 2024, the ORR assessed by IRC was 47.9% (56/117; 95% confidence interval: 38.5-57.3%). The incidence of treatment-related adverse events (TRAEs) of any grade was 97.5% (116/119). The incidence of grades 3 and 4 TRAEs was 38.7% (46/119). A total of 5.0% (6/119) of patients discontinued the treatment due to TRAEs. No treatment-related deaths occurred. Glecirasib exhibited promising clinical efficacy and manageable safety profiles in these patient populations. ClinicalTrials.gov identifier: NCT05009329.

基金：
Jacobio (Beijing)
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 生化与分子生物学 1 区 细胞生物学 1 区 医学：研究与实验
JCR分区：
出版当年[2025]版：
无
最新[2023]版：
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 CELL BIOLOGY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者：
第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted D, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp,Dept Med Oncol, Beijing, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Shi Yuankai,Fang Jian,Xing Ligang,et al.Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial[J].NATURE MEDICINE.2025,doi:10.1038/s41591-024-03401-z.
APA：
Shi, Yuankai,Fang, Jian,Xing, Ligang,Yao, Yu,Zhang, Jian...&Rao, Zhiyue.(2025).Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.NATURE MEDICINE,,
MLA：
Shi, Yuankai,et al."Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial".NATURE MEDICINE .(2025)

资源点击量：53699 今日访问量：0 总访问量：4607 更新日期：2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号